Aclaris Therapeutics ACRS Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's investing cash flow?
- Aclaris Therapeutics (ACRS) reported investing cash flow of -$30.93M in Q1 2026.
- How has Aclaris Therapeutics's investing cash flow changed year-over-year?
- Aclaris Therapeutics's investing cash flow decreased by 261.8% year-over-year, from $19.12M to -$30.93M.
- What is the long-term trend for Aclaris Therapeutics's investing cash flow?
- Over 2 years (2021 to 2025), Aclaris Therapeutics's investing cash flow has grown at a -46.3% compound annual growth rate (CAGR), from -$167.63M to $48.37M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.